Engineered T-reg Cell Therapy in Autoimmune Disease: From Preclinical to First-in-Human
Dr. Uladzislau Tsvirko
8 May 2026
Engineered regulatory T-cells aim to deliver tolerance to a defined target rather than suppress immunity broadly. A review of the two engineering strategies, the preclinical foundation, where the first-in-human programmes stand, and how this frontier relates to the polyclonal T-reg therapy used in practice today.
Why autoimmune disease is a target for engineered T-reg
Autoimmune diseases arise when the immune system loses tolerance to the body's own tissue. Regulatory T-cells (T-reg) are the cells that normally enforce that tolerance, and in many autoimmune conditions their number or function is reduced. The therapeutic logic is direct: restore or reinforce regulatory T-cell activity and the autoimmune attack should ease. Polyclonal T-reg therapy does this broadly across the immune network. Engineered T-reg therapy attempts to do it with precision, directing regulatory cells to the exact tissue or antigen under attack.
Two engineering strategies: CAR and TCR
Two designs dominate the field. A CAR-Treg carries a chimeric antigen receptor, a synthetic receptor that recognises a surface antigen and activates the cell wherever that antigen appears. A TCR-Treg instead uses an engineered T-cell receptor, which recognises a fragment of a protein presented on the cell surface, allowing it to respond to intracellular targets that a chimeric receptor cannot reach. Abata Therapeutics' ABA-101 for progressive multiple sclerosis is a TCR-Treg; Sangamo's TX200 and Quell's QEL-001 and QEL-005 are CAR-Tregs. Both pursue the same goal: antigen-specific tolerance instead of broad suppression.
The preclinical foundation
The move into patients rests on more than a decade of preclinical work showing that antigen-directed regulatory T-cells can suppress inflammation locally, protect target tissue, and induce lasting tolerance in animal models of transplantation and autoimmunity. Reviews in Frontiers in Immunology and related journals through 2024 and 2025 map a consistent picture: engineered T-reg can be more potent than polyclonal cells at the site of disease, provided they retain their regulatory identity once activated.
First-in-human: where the programmes stand
The clinical frontier remains early. Sangamo dosed the first human CAR-Treg in 2022 in kidney transplantation, the Phase 1/2 STEADFAST study. Quell has run QEL-001 in liver transplantation and, in March 2026, opened the Phase 1/2 CHILL study of QEL-005 in refractory rheumatoid arthritis and systemic sclerosis. Abata's ABA-101 entered first-in-human testing for multiple sclerosis, an early-phase study (NCT06566261). A wider biotech pipeline, including Sonoma Biotherapeutics, GentiBio, Kyverna and Tr1X, is advancing further engineered-T-reg and tolerance programmes. None has yet reported pivotal efficacy data.
The challenge of stability and manufacturing
Two problems define the engineering effort. The first is stability: a regulatory T-cell placed in an inflamed environment can lose its suppressive phenotype and turn inflammatory, which is why programmes build in safeguards such as Quell's FoxP3 Phenotype Lock. The second is manufacturing: each engineered product requires genetic modification, controlled expansion and rigorous quality control, which keeps early trials small and slow to read out.
How this relates to polyclonal T-reg therapy today
Engineered T-reg is the research frontier; polyclonal T-reg therapy is what is available and in use, including at BioCells Medical. Polyclonal cells act across the whole dysregulated immune network rather than a single antigen, which suits diseases driven by many targets at once, and they carry an established safety profile. Following the engineered field closely is part of how a cell-therapy clinic stays current, but the therapy a patient can receive today is the polyclonal regulatory T-cell approach from which the engineered work grew.